Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
In the study, the partners will perform exome sequencing and whole-genome array genotyping on more than 9,000 individuals with diabetes or with diabetic relatives.
Geisinger Health System's MyCode Community Health Initiative has signed up more than 100,000 participants and has returned results to about 100 patients.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
Independent research groups garnered evidence that mutations to the ANGPTL4 gene can lower blood triglyceride levels and reduce coronary artery disease risk.
Two executives of the Regeneron Genetics Center discuss the company's strategy for employing sequencing-based human genetics in drug discovery and development.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
